Alaunos Therapeutics Files 8-K on Agreements and Equity Sales
Ticker: TCRT · Form: 8-K · Filed: May 23, 2025 · CIK: 1107421
| Field | Detail |
|---|---|
| Company | Alaunos Therapeutics, INC. (TCRT) |
| Form Type | 8-K |
| Filed Date | May 23, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, sec-filing
Related Tickers: TCRT
TL;DR
Alaunos Therapeutics (TCRT) filed an 8-K detailing material agreements and equity sales.
AI Summary
Alaunos Therapeutics, Inc. filed an 8-K on May 23, 2025, reporting on a material definitive agreement, unregistered sales of equity securities, and financial statements. The filing details events as of May 19, 2025, and includes information about the company's principal executive offices in Houston, TX.
Why It Matters
This 8-K filing provides crucial updates on material agreements and equity transactions, which can significantly impact the company's financial standing and future operations.
Risk Assessment
Risk Level: medium — 8-K filings often contain material information that can lead to significant stock price volatility.
Key Numbers
- 001-33038 — SEC File Number (Identifies the company's filing with the SEC.)
- 87-1475642 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Alaunos Therapeutics, Inc. (company) — Registrant
- May 19, 2025 (date) — Date of earliest event reported
- May 23, 2025 (date) — Filing date
- Houston, TX (location) — Principal executive offices
- Delaware (location) — State of incorporation
FAQ
What type of material definitive agreement was entered into by Alaunos Therapeutics?
The filing indicates the entry into a material definitive agreement but does not specify the nature of the agreement in the provided text.
What is the significance of the 'Unregistered Sales of Equity Securities' item?
This item suggests that the company has issued equity securities without registering them with the SEC, which can have implications for investors and regulatory compliance.
What are the principal executive offices of Alaunos Therapeutics?
The principal executive offices are located at 2617 Bissonnet St, Suite 225, Houston, TX 77005.
When was Alaunos Therapeutics incorporated?
The company is incorporated in Delaware.
What is the filing date of this 8-K report?
The filing date of this 8-K report is May 23, 2025.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 23, 2025 regarding Alaunos Therapeutics, Inc. (TCRT).